Zim Laboratories Ltd
Pharmaceuticals & Biotechnology | Small Cap
Zim Laboratories shows a mixed financial landscape. Revenue and asset growth are strong, alongside solid profitability driven by good gross profit and returns on assets and capital employed. The company maintains a strong equity position, indicating financial stability. However, liquidity is poor, with low current, quick, and cash ratios. Efficiency ratios are also weak, suggesting challenges in asset utilization. EPS and net income growth are concerning. While coverage ratios are mixed, with a reasonable interest coverage, the company does not distribute dividends. This overview suggests a need to address liquidity and efficiency while capitalizing on growth and profitability.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio6.00
- Financial Ratio4.00
- Profitability Ratio7.20
- Efficiency Ratio4.67
- Coverage Ratio5.60
- Solvency Ratio10.00
- Liquidity Ratio2.00
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekNeutral
- 1 MonthNeutral
Zim Laboratories shows a mixed financial landscape. Revenue and asset growth are strong, alongside solid profitability driven by good gross profit and returns on assets and capital employed. The company maintains a strong equity position, indicating financial stability. However, liquidity is poor, with low current, quick, and cash ratios. Efficiency ratios are also weak, suggesting challenges in asset utilization. EPS and net income growth are concerning. While coverage ratios are mixed, with a reasonable interest coverage, the company does not distribute dividends. This overview suggests a need to address liquidity and efficiency while capitalizing on growth and profitability.
Overall Valuation Score
P/E RATIO (TTM)
77.71
Industry Median
23.93
Small Cap Median
23.93
P/E RATIO
41.96
P/B RATIO
2.03
Industry Median
2.53
Small Cap Median
2.53
P/S RATIO
1.35
Industry Median
1.35
Small Cap Median
1.35
Others
PEG RATIO
1.41
EV/EBITDA RATIO
10.43
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹104.91 as on Jun 15, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company has strong revenue and asset growth. However, the negative earnings per share (EPS) growth and net income growth are concerning. The company's growth trajectory is promising in terms of revenue and assets, but profitability needs to catch up to ensure sustainable expansion.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 8.47 | 19.82 | -8.02 | 3.27 | -1.32 |
| Operating Profit Growth Rate | 2.5 | 26.83 | -21.15 | 7.32 | -31.82 |
| Earnings Per Share (EPS) Growth | 99.33 | 67.56 | -29.34 | -29.38 | -56.4 |
| Asset Growth Rate | 5.23 | 0 | 30.7 | 5.59 | 14.19 |
| Net Income Growth Rate | 114.29 | 60 | -29.17 | -29.41 | -50 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Financial ratios indicate areas of concern. Adjusted earnings per share and book value per share are low, while cash earnings per share is somewhat better. The company makes no dividend payments and has significant capital expenditures. It should focus on improving these financial metrics to bolster investor confidence and long-term sustainability.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 9.38 | 4.9 | 3.47 | 2.45 | 0.93 |
| Cash Earnings Per Share (Cash EPS) | 19.38 | 8.37 | 6.73 | 6.53 | 4.81 |
| Book Value Per Share | 109.38 | 41.02 | 48.78 | 51.63 | 55 |
| Dividend Per Share (DPS) | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 15.1 | 36.6 | 73.4 | 40.1 | 38.8 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability ratios show strengths and weaknesses. Gross profit margin, return on capital employed (ROCE), return on assets (ROA), and operating margin are robust. Return on equity (ROE) and net margin are low. The company is generating good returns on its capital and assets, but struggles to translate this into net profits and equity returns. Improving net margin and ROE should be a priority.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 7.51 | 8.77 | 6.81 | 6.33 | 2.67 |
| Return on Capital Employed (ROCE) | 12 | 17 | 10 | 8 | 5 |
| Return on Equity (ROE) | 8.57 | 11.94 | 7.11 | 4.74 | 2.02 |
| Return on Assets (ROA) | 11.99 | 15.2 | 9.17 | 9.32 | 5.57 |
| Operating Margin | 12.31 | 13.03 | 11.17 | 11.61 | 8.02 |
| Net Margin | 4.5 | 6.02 | 4.63 | 3.17 | 1.6 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
Efficiency ratios reveal mixed performance. While days sales in inventory and receivable days are high, suggesting effective working capital management, the fixed asset and capital turnover ratios are low. The company may not utilize its assets efficiently to generate revenue. While specific to the healthcare industry, addressing asset utilization could unlock further value.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 3.14 | 3.66 | 2.28 | 2.31 | 2.31 |
| Inventory Turnover Ratio | 4.78 | 5.64 | 5.07 | 4.25 | 4.04 |
| Receivables Turnover Ratio | 4.11 | 4.31 | 3.76 | 3.66 | 3.46 |
| Days Sales in Inventory Ratio | 76.36 | 64.72 | 71.99 | 85.88 | 90.35 |
| Receivable Days | 88.81 | 84.69 | 97.07 | 99.73 | 105.49 |
| Capital Turnover Ratio | 1.7 | 1.74 | 1.31 | 1.27 | 1.09 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's coverage ratios present a mixed picture. The interest coverage ratio is adequate, indicating the company can meet its interest obligations. The absence of dividend payments results in a low equity dividend coverage ratio. The ability to comfortably cover interest expenses is a positive sign, while dividend policies reflect capital allocation decisions.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 3.62 | 6.83 | 4.43 | 2.64 | 1.62 |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's solvency position appears strong, characterized by a high equity ratio and low debt ratios, indicating a reliance on equity financing rather than debt. While a debt-free status can be seen as a positive, it might also suggest missed opportunities for leveraging debt to fuel growth. The company's financial structure appears conservative, focusing on maintaining a strong equity base.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.11 | 0.12 | 0.15 | 0.15 | 0.13 |
| Debt to Equity Ratio | 0.12 | 0.14 | 0.18 | 0.18 | 0.15 |
| Equity Ratio | 0.89 | 0.88 | 0.85 | 0.85 | 0.87 |
| Debt To Asset Ratio | 0.06 | 0.08 | 0.09 | 0.1 | 0.09 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position is weak, indicating potential difficulties in meeting short-term obligations. The current, quick, and cash ratios are notably low, suggesting limited liquid assets. On a positive note, the company's operating cash flow might provide some support. The healthcare industry's specific working capital needs should be considered, but the low ratios raise concerns about financial flexibility.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.56 | 1.81 | 1.46 | 1.36 | 1.43 |
| Quick Ratio | 1.03 | 1.33 | 0.98 | 0.87 | 0.95 |
| Cash Ratio | 0.03 | 0.07 | 0.06 | 0.01 | 0.22 |
| Operating Cash Flow Ratio | 0.34 | 0.33 | 0.1 | 0.24 | 0.25 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 2 | SMS Lifesciences India Ltd | 6.59 | 21.78 | Neutral | 45.00 | 70.68 | 19.00 |
| 3 | Infinium Pharmachem Ltd | 6.42 | 26.49 | Neutral | 22.00 | 6.43 | 14.00 |
| 4 | Medicamen Biotech Ltd | 5.73 | 31.76 | Neutral | 20.00 | 6.94 | 10.00 |
| 5 | Aarey Drugs & Pharmaceuticals Ltd | 5.73 | 58.49 | Neutral | 7.00 | 1.40 | 4.00 |
| 6 | Albert David Ltd | 5.63 | -272.76 | Neutral | 5.00 | -2.62 | -1.00 |
| 7 | BPL Ltd | 5.46 | -31.34 | Neutral | -4.82 | -3.00 | -8.55 |
| 8 | Zim Laboratories Ltd | 5.41 | 41.96 | Neutral | 30.00 | 1.11 | 6.00 |
| 9 | Quest Laboratories Ltd | 5.27 | 11.86 | Neutral | 18.00 | 9.16 | 15.00 |
| 10 | Sotac Pharmaceuticals Ltd | 5.27 | 21.26 | Neutral | 18.00 | 4.45 | 6.00 |
| 11 | Lyka Labs Ltd | 4.77 | -24.93 | Neutral | -4.00 | -9.05 | -10.00 |
| 12 | Krebs Biochemicals & Industries Ltd | 4.16 | -5.14 | Highly Undervalued | -4.00 | -12.49 | -4.00 |
| 13 | Nectar Lifescience Ltd | 3.83 | -2.67 | Neutral | -59.00 | -2.95 | -293.00 |
The management of Zim Laboratories shows a mixed performance. A consistent operating profit margin and stable promoter holding are positive indicators. However, declining profit growth and increasing debt levels raise concerns. The inconsistent quarterly sales and profit growth indicate operational challenges. Despite a stable promoter holding, the financial performance and rising liabilities suggest a need for improvements in financial management and execution.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Operating Profit Margin | 12% | Stable operational efficiency |
| Promoter Holding | 33.26% | Consistent promoter confidence | |
| CONS | Profit Growth | -6% (3Y) | Declining profit growth |
| Debt/Equity Ratio | Increasing | Rising financial leverage |
Financial Performance & Growth
Zim Laboratories demonstrates inconsistent financial growth. While sales growth has been erratic, profit growth shows a concerning downward trend. The compounded Sales Growth indicates fluctuating performance, and the compounded Profit Growth is declining.
| Metric | 5 Years | 3 Years | TTM |
|---|---|---|---|
| Compounded Sales Growth | 6% | 4% | 3% |
| Compounded Profit Growth | 30% | -6% | -29% |
Quarterly sales growth has fluctuated significantly, with recent quarters showing volatility. For instance, YOY Sales Growth % ranged from 42.26% in Mar 2022 to -7.75% in Mar 2025. Similarly, YOY Profit Growth % has seen extreme variations, from 2,610.53% in Jun 2022 to -39.68% in Mar 2025. OPM has remained relatively stable, hovering around 12-14%, but this stability does not compensate for the inconsistencies in sales and profit growth. The fluctuations in sales & profit indicates volatility.
Capital Efficiency & Returns
The capital efficiency and returns for Zim Laboratories indicate areas of concern. While ROCE was at 17% in Mar 2023, it has declined to 8% by Mar 2025. ROE is also relatively low at 4.94%.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| ROCE % | 17% | 10% | 8% |
The Cash Conversion Cycle has lengthened, increasing from 75 days in Mar 2015 to 140 days in Mar 2025. This suggests inefficiencies in managing working capital. The company's ability to generate returns from its capital and equity is diminishing.
Financial Health & Prudence
Zim Laboratories' financial health presents a mixed outlook. The Debt/Equity ratio has been increasing.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Borrowings | 62 | 112 | 118 |
The company has not been distributing dividends. This could indicate a focus on reinvesting profits, but it also reduces immediate returns for shareholders.
Shareholding & Ownership Structure
The shareholding pattern of Zim Laboratories indicates stable ownership. The promoter holding has remained constant at 33.26% over the past few years. There is minimal FII and DII presence.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Promoter Holding | 33.26% | 33.26% | 33.26% |
The number of shareholders has increased significantly from 3,561 in Mar 2022 to 17,448 in Mar 2025, which implies growing investor interest.
The risk assessment for Zim Laboratories is moderate. The segment performance shows volatility from fluctuating sales and profit growth. This inconsistency raises concerns about the predictability of future earnings. The increasing debt levels also add to the risk profile.
Segment performance volatility
The segment performance of Zim Laboratories exhibits volatility, as evidenced by the fluctuating sales and profit growth. The quarterly sales growth rates have varied significantly, ranging from substantial increases to declines.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| YOY Sales Growth % | 42.26% | 0.33% | 11.81% | -7.75% |
| YOY Profit Growth % | 353.55% | 2.99% | 11.74% | -39.68% |
This indicates potential challenges in maintaining consistent operational performance.
Foreign exchange or interest rate exposure
The company's increasing interest expenses indicate a growing exposure to interest rate risk. The interest payments have risen.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Interest | 8 | 6 | 7 | 11 |
This could affect profitability.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe